Methyl-MMDA-2
 | |
| Clinical data | |
|---|---|
| Other names | METHYL-MMDA-2; 2-Methoxy-4,5-methylenedioxy-N-methylamphetamine; 6-Methoxy-MDMA |
| Routes of administration | Oral[1] |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Duration of action | Unknown[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H17NO3 |
| Molar mass | 223.272 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Methyl-MMDA-2, also known as 2-methoxy-4,5-methylenedioxy-N-methylamphetamine or as 6-methoxy-MDMA, is a psychoactive drug of the phenethylamine, amphetamine, and MDxx families.[1] It is the N-methylated derivative of MMDA-2, and it is also an analogue of MDMA and 6-methyl-MDA.[1]
Use and effects
[edit]Methyl-MMDA-2 was first synthesized by Alexander Shulgin and was described in his book PiHKAL (Phenethylamines I Have Known and Loved). He states that it is essentially inactive at a dose of 70 mg orally, and he did not test higher doses;[1] however, Methyl-MMDA-2 is still likely to be active, perhaps in the 125 to 250 mg range.[citation needed] This reduction in hallucinogenic activity relative to MMDA-2 parallels that of MDA and MDMA, indicating that with phenethylamines, N-methylation substantially reduces 5-HT2A receptor affinity.[1][2]
Chemistry
[edit]Synthesis
[edit]The chemical synthesis of methyl-MMDA-2 has been described.[1]
